ArticleDiabetology & metabolic syndrome2022
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease.
Article in Diabetology & metabolic syndrome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Inverse association between metabolic dysfunction-associated steatotic liver disease and incident rheumatoid arthritis in middle-aged adults with chronic hepatitis B.Clinical rheumatology · 2026Article
- Exploring the liver-kidney axis in the Ghanaian population: the RODAM prospective study.Journal of global health · 2026Article
- Recent advances in the treatment of chronic liver diseases: focus on MASLD/MASH-related fibrosis.Clinical and experimental hepatology · 2026Review
- Discordance Between Conventional Ultrasound and Transient Elastography in Hepatic Steatosis Assessment: Clinical Factors Associated with Discrepant Findings.Diagnostics (Basel, Switzerland) · 2026Article
- Statin use and the risk of liver-related events in older adults with steatotic liver disease.Scientific reports · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study.Hepatology international · 2026Article
- Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study.Scientific reports · 2025Article
- Association between cholecystectomy and the risk of new-onset metabolic dysfunction-associated steatotic liver disease: a risk-stratified cohort study.Scientific reports · 2025Article
- Adherence to plant based diets reduce the risk of hepatic fibrosis in nonalcoholic fatty liver disease.Scientific reports · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.Diabetes & metabolism journal · 2025Article
- The Relationship of Fatty Liver with Body Composition Indices in Individuals with Metabolic Disorders - A Cross-Sectional Study.Pakistan journal of medical sciences · 2025Article
- Association of high serum aspartate transaminase to high density lipoprotein-cholesterol ratio with probable dementia among people living with HIV on antiretroviral therapy in Southwestern Uganda.SAGE open medicine · 2025Article
- Fatty liver index and risk of type 2 diabetes of adults with normoglycemia: Insights into insulin sensitivity and beta-cell function.PloS one · 2025Article
- Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects: A Population-Based Study.Nutrients · 2024Article
- Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test.World journal of gastroenterology · 2024Article
- Protective Effect of High Adherence to Mediterranean Diet on the Risk of Incident Type-2 Diabetes in Subjects with MAFLD: The Di@bet.es Study.Nutrients · 2024Article
- Association between magnesium depletion score and the risk of metabolic dysfunction associated steatotic liver disease: a cross sectional study.Scientific reports · 2024Article
- Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity; Patient Characteristics and Association with Leptin-A Cross-Sectional Overview of Baseline Data from a RCT.Children (Basel, Switzerland) · 2024Article
- Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity.Journal of the Endocrine Society · 2024Article
- [Hypothetical Alcohol Consumption Interventions and Hepatic Steatosis: A Longitudinal Study in a Large Cohort].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
aimsMetabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature for nonalcoholic fatty liver. Along with obesity, fatty liver associated with metabolic dysfunction is increasing and has become a serious socioeconomic problem. Non-invasive testing for the confirmation of MAFLD, including the fatty liver index (FLI), can be used as an alternative method for diagnosing steatosis when imaging modalities are not available. To date, few studies have examined the effectiveness and validity of FLI for diagnosing MAFLD. Therefore, this study analyzed the effectiveness and validity of FLI for diagnosing MAFLD.
methodsMedical records of men and women aged ≥ 19 years who underwent abdominal computed tomography (CT) examination at our facility between March 2012 and October 2019 were retrospectively reviewed. A comparative analysis between non-continuous variables was performed using the chi-squared test. The area under receiver operating characteristic (AUROC) curve was used to verify the effectiveness of FLI as a predictive index for MAFLD.
resultsAnalysis of the association between MAFLD and abdominal CT revealed that the sensitivity and specificity of FLI for diagnosing MAFLD were 0.712 and 0.713, respectively. The AUROC of FLI for predicting MAFLD was 0.776.
conclusionsOur study verified the accuracy of FLI for predicting MAFLD using CT. The FLI can be used as a simple and cost-effective tool for screening MAFLD in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.